Cargando…
A combination pharmacotherapy of tapentadol and pregabalin to tackle centrally driven osteoarthritis pain
BACKGROUND: Many Osteoarthritis (OA) patients report with clinical features to their pain that cannot be explained by purely peripheral mechanisms. Yet, the analgesic agents available that tackle centrally driven chronic pain often provide only partial pain relief, or have dose‐limiting side effects...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6618140/ https://www.ncbi.nlm.nih.gov/pubmed/30821870 http://dx.doi.org/10.1002/ejp.1386 |
_version_ | 1783433851974975488 |
---|---|
author | Lockwood, Stevie Margaret Dickenson, Anthony H. |
author_facet | Lockwood, Stevie Margaret Dickenson, Anthony H. |
author_sort | Lockwood, Stevie Margaret |
collection | PubMed |
description | BACKGROUND: Many Osteoarthritis (OA) patients report with clinical features to their pain that cannot be explained by purely peripheral mechanisms. Yet, the analgesic agents available that tackle centrally driven chronic pain often provide only partial pain relief, or have dose‐limiting side effects. We explored a combination therapy of the centrally acting analgesic agents tapentadol and pregabalin, to investigate if they could be used in combination to provide superior analgesia. METHODS: Using electrophysiological single‐unit recordings taken from spinal wide dynamic range neurons, Diffuse Noxious Inhibitory Controls (DNIC) were assessed as a marker of potential changes in descending controls in a monoiodoacetate (MIA) model of OA. We investigated if a subcutaneous injection of tapentadol or pregabalin, both alone and in combination, inhibited neuronal responses and restored the expression of DNIC, quantified as a reduction in neuronal firing in the presence of a conditioning noxious stimulus. RESULTS: Tapentadol restored DNIC‐induced neuronal inhibition in MIA animals, while pregabalin inhibited pre‐conditioned mechanically evoked neuronal responses but did not restore DNIC. Given in combination, tapentadol and pregabalin restored DNIC expression and also inhibited spinal neuronal responses. CONCLUSIONS: We propose that there is both central sensitization and an imbalance in inhibitory and facilitatory descending controls in MIA animals. The combination therapy of tapentadol and pregabalin restored descending noradrenergic inhibitory tone and also inhibited nociceptive transmission at the level of the spinal cord. SIGNIFICANCE: This study shows that pregabalin and tapentadol target different mechanisms of centrally driven chronic pain associated with osteoarthritis, and that when administered together can restore descending inhibitory tone whilst also tackling spinal neuronal hyperexcitability and may therefore provide superior analgesia. |
format | Online Article Text |
id | pubmed-6618140 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-66181402019-07-22 A combination pharmacotherapy of tapentadol and pregabalin to tackle centrally driven osteoarthritis pain Lockwood, Stevie Margaret Dickenson, Anthony H. Eur J Pain Original Articles BACKGROUND: Many Osteoarthritis (OA) patients report with clinical features to their pain that cannot be explained by purely peripheral mechanisms. Yet, the analgesic agents available that tackle centrally driven chronic pain often provide only partial pain relief, or have dose‐limiting side effects. We explored a combination therapy of the centrally acting analgesic agents tapentadol and pregabalin, to investigate if they could be used in combination to provide superior analgesia. METHODS: Using electrophysiological single‐unit recordings taken from spinal wide dynamic range neurons, Diffuse Noxious Inhibitory Controls (DNIC) were assessed as a marker of potential changes in descending controls in a monoiodoacetate (MIA) model of OA. We investigated if a subcutaneous injection of tapentadol or pregabalin, both alone and in combination, inhibited neuronal responses and restored the expression of DNIC, quantified as a reduction in neuronal firing in the presence of a conditioning noxious stimulus. RESULTS: Tapentadol restored DNIC‐induced neuronal inhibition in MIA animals, while pregabalin inhibited pre‐conditioned mechanically evoked neuronal responses but did not restore DNIC. Given in combination, tapentadol and pregabalin restored DNIC expression and also inhibited spinal neuronal responses. CONCLUSIONS: We propose that there is both central sensitization and an imbalance in inhibitory and facilitatory descending controls in MIA animals. The combination therapy of tapentadol and pregabalin restored descending noradrenergic inhibitory tone and also inhibited nociceptive transmission at the level of the spinal cord. SIGNIFICANCE: This study shows that pregabalin and tapentadol target different mechanisms of centrally driven chronic pain associated with osteoarthritis, and that when administered together can restore descending inhibitory tone whilst also tackling spinal neuronal hyperexcitability and may therefore provide superior analgesia. John Wiley and Sons Inc. 2019-03-22 2019-07 /pmc/articles/PMC6618140/ /pubmed/30821870 http://dx.doi.org/10.1002/ejp.1386 Text en © 2019 The Authors. European Journal of Pain published by John Wiley & Sons Ltd on behalf of European Pain Federation ‐ EFIC ® This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Lockwood, Stevie Margaret Dickenson, Anthony H. A combination pharmacotherapy of tapentadol and pregabalin to tackle centrally driven osteoarthritis pain |
title | A combination pharmacotherapy of tapentadol and pregabalin to tackle centrally driven osteoarthritis pain |
title_full | A combination pharmacotherapy of tapentadol and pregabalin to tackle centrally driven osteoarthritis pain |
title_fullStr | A combination pharmacotherapy of tapentadol and pregabalin to tackle centrally driven osteoarthritis pain |
title_full_unstemmed | A combination pharmacotherapy of tapentadol and pregabalin to tackle centrally driven osteoarthritis pain |
title_short | A combination pharmacotherapy of tapentadol and pregabalin to tackle centrally driven osteoarthritis pain |
title_sort | combination pharmacotherapy of tapentadol and pregabalin to tackle centrally driven osteoarthritis pain |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6618140/ https://www.ncbi.nlm.nih.gov/pubmed/30821870 http://dx.doi.org/10.1002/ejp.1386 |
work_keys_str_mv | AT lockwoodsteviemargaret acombinationpharmacotherapyoftapentadolandpregabalintotacklecentrallydrivenosteoarthritispain AT dickensonanthonyh acombinationpharmacotherapyoftapentadolandpregabalintotacklecentrallydrivenosteoarthritispain AT lockwoodsteviemargaret combinationpharmacotherapyoftapentadolandpregabalintotacklecentrallydrivenosteoarthritispain AT dickensonanthonyh combinationpharmacotherapyoftapentadolandpregabalintotacklecentrallydrivenosteoarthritispain |